Semaglutide vs Tirzepatide

How do they actually differ?

Evidence tier: 1 — mechanism and pharmacokinetics established by FDA-approval-grade RCT programs (STEP, SUSTAIN, SURMOUNT, SURPASS).

Semaglutide is a single-target GLP-1 receptor agonist; tirzepatide is a dual GLP-1 and GIP receptor agonist. Both are weekly subcutaneous injections, both work primarily through delayed gastric emptying, central appetite suppression, and glucose-dependent insulin release. The added GIP signaling on tirzepatide produces measurably greater weight loss, faster A1c reduction in T2D, and a slightly different gastrointestinal tolerability curve — most patients reach an effective dose with fewer titration steps. Semaglutide has the longer half-life (~165 hours) and a deeper outcomes-trial portfolio across cardiovascular, renal, and hepatic endpoints. Tirzepatide has the shorter half-life (~120 hours) but produces stronger reductions in body weight and waist circumference. Both share the same boxed warning for thyroid C-cell tumors based on rodent carcinogenicity studies, and the same general adverse-event profile dominated by nausea, vomiting, and diarrhea concentrated in the titration phase. Mechanistically they are not interchangeable: tirzepatide adds a pathway, it does not just amplify GLP-1 signaling. The comparisonMatrix has the dosing and pricing detail.

Who should choose semaglutide?

Evidence tier: 1 — SELECT trial established cardiovascular benefit in obesity without diabetes (Lincoff 2023), and FLOW established renal benefit in T2D with CKD.

Semaglutide is the better fit for patients whose primary clinical concern is cardiovascular protection rather than maximum weight loss. SELECT enrolled 17,604 patients with established cardiovascular disease and obesity but no diabetes, and showed a 20% reduction in major adverse cardiovascular events on semaglutide 2.4 mg weekly versus placebo. Wegovy now carries the FDA label for cardiovascular risk reduction in this population — tirzepatide does not, pending the SURPASS-CVOT readout in 2027. Semaglutide also has the longer track record in chronic kidney disease (Ozempic post-FLOW), in MASH (post-ESSENCE), and in older patients in general because it has been on the market longer. The oral formulation (Rybelsus) is unique to semaglutide — patients with severe needle aversion or who travel internationally where injectables are difficult may prefer the oral route despite its lower bioavailability. Patients already on Ozempic or Wegovy with adequate weight loss and good tolerability have no clinical reason to switch. Patients with a strong preference for the longer half-life and gentler titration curve also lean semaglutide. Discuss the trade-off between maximum weight loss and accumulated outcomes evidence with your physician.

Who should choose tirzepatide?

Evidence tier: 1 — SURMOUNT-5 directly demonstrated superior weight loss; SURPASS-2 demonstrated superior glycemic control versus semaglutide.

Tirzepatide is the better fit for patients whose primary goal is maximum weight loss, whose diabetes is poorly controlled on a GLP-1 monotherapy, or who carry an obstructive sleep apnea diagnosis. SURMOUNT-5 — the only head-to-head trial in obesity without T2D — produced a 20.2% mean weight loss on tirzepatide versus 13.7% on semaglutide at 72 weeks, with 65% of tirzepatide patients reaching 15% weight loss versus 32% of semaglutide patients. Discontinuation rates from gastrointestinal adverse events were actually lower on tirzepatide (2.7%) than on semaglutide (5.6%) in that trial. Zepbound is the only GLP-1-class agent FDA-approved for moderate-to-severe OSA in obesity (December 2024); semaglutide does not carry this indication. Patients who plateaued on semaglutide are also candidates for tirzepatide because the additional GIP pathway is mechanistically additive. The titration is also shorter to reach an effective range — clinicians often find this easier in practice. Patients with established cardiovascular disease without an obesity-driven indication should not default to tirzepatide while SURPASS-CVOT remains pending. Discuss the indication-versus-efficacy trade-off with your physician.

What does the evidence base actually say?

Evidence tier: 1 — multiple Phase 3 RCTs, one direct head-to-head in obesity (SURMOUNT-5), one in T2D (SURPASS-2), plus large cardiovascular outcomes trials.

The semaglutide evidence base began with the STEP program: STEP-1 produced 14.9% mean weight loss at 68 weeks in adults with obesity without diabetes. The class-defining cardiovascular outcomes trial is SELECT, which read out in 2023 with a 20% MACE reduction in 17,604 patients. The tirzepatide evidence base began with SURMOUNT-1, which produced 16-22.5% weight loss across 5/10/15 mg doses at 72 weeks. The two programs intersected directly twice: SURPASS-2 (T2D, 2021) showed tirzepatide superior to semaglutide 1 mg on both A1c and weight, and SURMOUNT-5 (2025) showed tirzepatide 10/15 mg superior to semaglutide 1.7/2.4 mg on weight loss in obesity without T2D. SURMOUNT-4 established that tirzepatide withdrawal produces substantial weight regain (14% gain on placebo vs 5.5% loss continuing) — the same pattern documented for semaglutide in STEP-4. Neither drug has 10-year safety data; both have the boxed C-cell warning. SURPASS-CVOT for tirzepatide is the next major readout in this class, expected 2027. Until then, the cardiovascular indication belongs to semaglutide.

Cost, access, and regulatory comparison

Evidence tier: 2 — pricing and access reflect April 2026 US-market reality and are subject to change.

Branded retail in the US runs ~$1,350/month for Wegovy and ~$1,060/month for Zepbound at full list price — Lilly's direct-pay program brought tirzepatide pricing below semaglutide. Insurance coverage is increasingly common for both in T2D, less consistent for obesity, and expanding for tirzepatide post-OSA approval. Both are widely covered for established cardiovascular disease (semaglutide post-SELECT) and for sleep apnea (tirzepatide post-SURMOUNT-OSA). Compounded versions of both drugs proliferated during the 2023-2024 shortages but are now restricted under the FDA "essentially a copy" doctrine; access varies state-by-state. Both carry boxed thyroid C-cell warnings and contraindications in MEN-2 and personal/family medullary thyroid cancer. Patents on Wegovy/Ozempic begin to expire post-2031; on Mounjaro/Zepbound post-2032. Both are Schedule-unscheduled, prescription-only. Off-label use in non-obese populations or for cosmetic weight loss is contested by payers and increasingly by state medical boards. See the FDA Wegovy label and FDA Zepbound label for current prescribing information.

Related on Peptide Story

• Semaglutide fact box
• Tirzepatide fact box
• Weight Loss pillar guide
• Tapering off GLP-1s without rebound
• GLP-1 muscle preservation

References

• Aronne LJ, Horn DB, le Roux CW, et al. 2025. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. PMID 40353578
• Frias JP, Davies MJ, Rosenstock J, et al. 2021. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. PMID 34170647
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. 2022. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. PMID 35658024
• Wilding JPH, Batterham RL, Calanna S, et al. 2021. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. PMID 33567185
• Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. 2023. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. PMID 37952131
• Aronne LJ, Sattar N, Horn DB, et al. 2024. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. PMID 38078870